Varun Beverages Reported Third-Quarter Profit Growth on Higher Revenue, Margin
By Kosaku Narioka
Varun Beverages reported growth in net profit in the third quarter, thanks to increased revenue and higher margins.
The Indian soft-drink maker and PepsiCo franchisee said Monday that net profit rose 32% from a year earlier to 5.01 billion rupees ($60.2 million) for the three months ended Sept. 30 from INR3.81 billion a year earlier. That beat the estimate of INR4.76 billion in a poll of analysts by FactSet.
Third-quarter revenue increased 21% from a year earlier to INR39.38 billion, thanks to sales growth in Indian and international markets, said Varun, which operates in the South Asian nation, its neighboring countries and Africa.
Third-quarter gross profit margin improved to 55.3% from 53.7% a year earlier, primarily because of the softening of materials costs for plastic bottles, it said.
Varun Chairman Ravi Jaipuria said the company was taking strategic initiatives to strengthen its position in the global beverage industry and that a facility in the Democratic Republic of the Congo was expected to be commissioned in the coming months.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
November 06, 2023 05:31 ET (10:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks